Rezafungin
- Generic Name
- Rezafungin
- Brand Names
- Rezzayo
- Drug Type
- Small Molecule
- Chemical Formula
- C63H85N8O17
- CAS Number
- 1396640-59-7
- Unique Ingredient Identifier
- G013B5478J
- Background
Rezafungin is an echinocandin antifungal drug. Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily....
- Indication
Rezafungin is indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
- Associated Conditions
- Candidemia, Invasive Candidiasis
- Associated Therapies
- -
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Cidara Therapeutics reports Q3 2024 financials, highlights Phase 2b NAVIGATE trial for CD388 influenza prophylaxis, restructuring to focus on CD388 development, and presentations at 2024 IDWeek and OPTIONS XII conferences. Cash and equivalents total $127.4 million, with net loss of $16.0 million for Q3 2024.
How Cidara Got Its Molecule Back
Cidara Therapeutics regained control of its lead drug-Fc conjugate, CD388, after Janssen Pharmaceuticals exited infectious disease development. Cidara raised $240 million to support a phase 2b study and divested its interests in rezafungin to focus on CD388. The drug aims to provide universal flu prevention through a novel approach combining a small molecule with the Fc portion of a human antibody, offering potential advantages over traditional vaccines and therapeutics.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath